TIMELINE-Key dates in Genzyme's manufacturing crisis

Fri Aug 13, 2010 6:06pm EDT

Aug 13 (Reuters) - U.S. biotechnology company Genzyme Corp GENZ.O, a maker of extremely expensive lifesaving medicines for rare genetic disorders, is considering an acquisition offer by French drugmaker Sanofi-Aventis (SASY.PA).

A key focus of any talks will be Genzyme's ability to move past a viral contamination at its main plant that caused severe shortages of its most important products. [ID:nN12260234]

The manufacturing crisis has punished Genzyme's earnings and share price and made it more vulnerable to dissident investors. Analysts say it may also strengthen Sanofi's case that a deal price reflect the risk in fixing those problems.

The following is a timeline of significant developments:


March 2 - Company discloses FDA warning letter identifying manufacturing deficiencies at Allston, Massachusetts plant.

June 16 - Discloses viral contamination leading to shutdown and severe shortages of key drugs Cerezyme and Fabrazyme.

July 16 - Due to Cerezyme shortage, Shire (SHP.L) gets FDA fast track designation for experimental Gaucher treatment.

July 31 - FDA says will reinspect Allston after company fails to take sufficient action on process control problems.

Aug. 14 - Only those in most need get Cerezyme in Europe.

Aug. 25 - FDA grants fast track review to Protalix BioTherapeutics (PLX.A) experimental Gaucher disease drug to help address shortage; Pfizer (PFE.N) later acquires rights.

Nov. 13 - FDA says five drugs made at Allston have unacceptable levels of steel fragments, other contaminants.

Dec. 1 - Newly made Cerezyme begins shipping from Allston.


Jan. 4 - Genzyme announces deal for Hospira Inc (HSP.N) to take on some filling and packaging for several products.

Jan. 7 - Genzyme agrees to appoint activist investor Ralph Whitworth of Relational Investors to board; reports surface that billionaire investor Carl Icahn may mount a proxy battle.

Jan. 8 - Ron Branning appointed to head global quality.

Jan. 12 - Newly made Fabrazyme beings shipping.

Feb. 3 - Company appoints former Eli Lilly (LLY.N) executive Scott Canute as global manufacturing chief.

Feb. 22 - Company receives notice that Icahn intends to nominate four candidates to board.

Feb. 26 - FDA approves Shire Gaucher disease drug.

March 24 - Genzyme says FDA to take enforcement action, likely including imposing fines, over manufacturing crisis.

April 15 - Whitworth joins board in move to rebuff Icahn.

April 21 - Genzyme says expects to pay $175 million penalty from past profits and possibly future fines under draft consent decree deal; discloses a March power outage affecting water at Allston, worsening Cerezyme and Fabrazyme supply shortage.

May 6 - Under pressure from investors Genzyme says will look into selling three non-core businesses -- genetic testing, diagnostic products and pharmaceutical materials.

May 17 - Icahn doubles stake to about 10.5 million shares.

May 24 - Consent decree finalized. In addition to $175 million penalty, company to move filling and packaging out of Allston, place manufacturing under oversight of a third party.

May 26 - Icahn urges board to remove CEO Henri Termeer.

June 9 - Icahn reaches accord with Genzyme, abandons proxy fight and gets two representatives on board.

June 29 - Still struggling with supply shortages, Genzyme says expects to meet 50 percent of Cerezyme demand for July.

July 21 - Genzyme takes $21.9 million write-off in second quarter due to products discarded over quality issues.

July 23 - Sources tell Reuters that French drugmaker Sanofi-Aventis made acquisition approach to Genzyme.

July 28 - Sanofi votes to move ahead with formal offer of up to $18.7 billion to acquire Genzyme, sources say.

Aug. 2 - Sanofi sends $69/share takeover proposal to Genzyme, sides discussing offer, sources say.

Aug. 9 - Company discloses additional $6.5 million write-off for discarded products due to quality issues that turn second quarter results from flat to a loss.

Aug. 10 - Company says it will take three to four years to rectify manufacturing problems at Allston.


Nov. 28, 2010 - Genzyme must finish transition of filling and finishing of products intended for U.S. from Allston; to be done in Genzyme plant in Ireland, Hospira plant in Kansas.

Aug. 31, 2011 - Filling and finishing of products intended for sale outside U.S. must transfer from Allston; While bulk of Cerezyme, Fabrazyme manufacturing will continue in Allston, filling and packaging will cease there.

Late 2011: Genzyme anticipates FDA approval of new plant in Framingham, Massachusetts that will expand manufacturing capacity for Fabrazyme and later Cerezyme. (Compiled by Bill Berkrot. Editing by Michele Gershberg)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.